The present invention relates to recombinant BCG expressing HIV-1 p24 using pMyong2 vector system and its use as an HIV-1 vaccine, wherein rBCG-pMyong2-p24, a pMyong2 vector system, contains rBCG and infected antigen presenting cells (APC). Induction of HIV-1 p24 gag expression and high levels of HIV-1 gag-specific CD4 and CD8 T lymphocyte proliferation compared to rBCG-pAL-p24 in pAL5000 derived from the vector system. , Gamma interferon ELISPOT cell induction, antibody production, and cytotoxic T cell (CTL) responses were found to induce an enhanced p24 specific immune response in vaccinated mice, rBCG-pMyong2-p24 being the same pMyong2 The vector system was found to show higher p24-specific Ab production levels than rSmeg-pMyong2-p24. Thus, by confirming that recombinant BCG expressing HIV-1 p24 using rBCG-pMyong2-p24 according to the present invention induces an enhanced immune response to HIV-1 infection in a mouse model system, rBCG-pMyong2-p24 It is expected to be used as a major vaccine in heterologous prime-boost vaccine strategies for HIV-1 infection.
展开▼
